4th International Bladder Cancer Update

Virtual CME Symposium

April 28, 2021  |  6:00pm-9:30pm EDT (starting at 5pm CT/4pm MT/3pm PT)

innovations in urologic practice logo

Overview

The International Bladder Cancer Update (IBCU) is a CME-accredited conference focused on the diagnosis and treatment of bladder cancer. Due to the COVID-19 pandemic, the 4th IBCU has been converted to a virtual, one-evening event. The virtual conference offers medical professionals an opportunity to learn from expert international faculty to improve knowledge, participate in interactive live discussion panels, and evaluate best treatment practices to improve patient outcomes.

Co-Chair

Michael S. Cookson, MD, MMHC

Michael S. Cookson, MD, MMHC

Professor and Chairman of the Department of Urology
University of Oklahoma College of Medicine
Norman, OK

Co-Chair

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD

Director of the Genitourinary Oncology Section
Yale Cancer Center
New Haven, CT

Keynotes from Thought Leaders

Attend Sessions

Connect with peers and experts

How the Virtual CME Program Works

The virtual, Zoom-based event is open to all Grand Rounds in Urology members and the larger urology community.

Agenda

The 4th International Bladder Cancer Update (IBCU4) offers a robust online program with multi-track session broadcast, chat, exclusive interviews, and more. Join us for the full virtual conference on Wednesday, April 28, from 6:00pm-9:30pm EDT.

Wednesday, April 28, 2021

6:00pm-6:10pm

Introduction 
Program Co-Directors: Michael S. Cookson, MD, MMHC and Daniel P. Petrylak, MD

6:10pm-6:25pm

AUA/SUO/ASTRO MIBC Guidelines Review 
Michael S. Cookson, MD, MMHC

6:25pm-6:35pm

Lecture on Biomarkers in Bladder Cancer
Siamak Daneshmand, MD

6:35pm-6:50pm

Panel Discussion on Cxbladder Genomic Urine Test for Bladder Cancer (non-CME)
Moderator: Siamak Daneshmand, MD
Discussants: Sima P. Porten, MD, and Anne K. Shuckman, MD

6:50pm-7:00pm

Overview of Available Treatment Options in Metastatic Bladder Cancer 
Daniel P. Petrylak, MD

7:00pm-7:45pm

Spotlight Lecture/Product Theater (non-CME)
A Treatment Approach for Certain Patients with High-Risk Non-Muscle Invasive Bladder Cancer
Speaker: Neal D. Shore, MD

Learning Objectives:

  • Review the features of NMIBC
  • Evaluate the clinical data on a treatment option for certain patients with high-risk NMIBC
  • Understand the safety data associated with this treatment option for certain patients with high-risk NMIBC

Supported by Merck

7:45pm-8:00pm

Continuation of Update on Available Treatment Options in Metastatic Bladder Cancer 
Petros Grivas, MD, PhD

8:00pm-8:15pm

Lecture on Blue Light vs. White Light Cystoscopy
Sanjay Patel, MD

8:15pm-8:30pm

Panel Discussion on Gene Therapy for BCG-Unresponsive Patients (live)
Moderator: Daniel P. Petrylak, MD
Discussants: Colin P. Dinney, MD, and Seth P. Lerner, MD

8:30pm-9:15pm

Spotlight Lecture/Product Theater (non-CME)
The Role of the First FDA-Approved Kinase Inhibitor of FGFR3 or 2 
Genetic Alterations for the Treatment of Locally Advanced or 
Metastatic Urothelial Carcinoma (mUC) in Patients Who Have Received Prior Platinum-Based Therapy
Speaker: Gordon Brown, DO, FACOS

Supported by Janssen Biotech

9:15pm-9:30pm

Updates in Upper Tract Urothelial Cancer
Seth P. Lerner, MD

9:30pm

Concluding Remarks and Adjourn 
Daniel P. Petrylak, MD

Invited Faculty

Michael S. Cookson, MD, MMHC

Michael S. Cookson, MD, MMHC

IBCU Co-Chair

University of Oklahoma
Norman, Oklahoma

Daniel P. Petrylak, MD

Daniel P. Petrylak, MD

IBCU Co-Chair

Yale Cancer Center
New Haven, Connecticut

Siamak Daneshmand, MD

Siamak Daneshmand, MD

University of Southern California
Los Angeles, California

Colin N.P. Dinney, MD

Colin N.P. Dinney, MD

MD Anderson Cancer Center
Houston, Texas

Petros Grivas, MD, PhD

Petros Grivas, MD, PhD

University of Washington
Seattle, Washington

Seth P. Lerner, MD

Seth P. Lerner, MD

Baylor College of Medicine
Houston, Texas

Sanjay G. Patel, MD

Sanjay G. Patel, MD

University of Oklahoma
Norman, Oklahoma

CME Information

Medical Education Resources designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Meeting Objectives:

  1. Assess the MIBC Guidelines from AUA, SWOG, and ASTRO
  2. Evaluate the role of novel or emerging agents in the treatment of UTUC
  3. Recognize the impact of current clinical trial data on the treatment of patients with bladder cancer
  4. Discuss the treatment of BCG-Unresponsive patients
  5. Evaluate recent clinical trial results investigating PARP inhibition, immunotherapy, and other new combination therapies for the treatment of urothelial bladder cancer

Registration

During these times, Grand Rounds in Urology and the International Bladder Cancer Update are committed to you and helping your practice run as best as it can.

Support Opportunities

To inquire about support opportunities, please contact:

Marc Weathersby, Chief Marketing Officer
Tel:434-817-2000, x193    Cell: 434-989-5508
Fax 434-817-2020    mweathersby@cjp.com

Exhibit and Sponsor Prospectus

Meeting organized by Grand Rounds in Urology, a division of Carden Jennings Publishing, Co., Ltd.

Jointly provided by Medical Education Resources and Carden Jennings Publishing Co., Ltd.

=

Have Questions? Contact Us.